BXRX is a specialty pharma spun out of REPH during 11/19
Its lead asset is the recently approved Meloxicam for pain control in acute settings.
One of the reasons this stock has been crushed in 2020 is management's decision to implement a cashless warrant conversion. In essence, BXRX issued 9.8M shares w/o getting a dime for them.
On 8/20 BXRX current assets were ~20M
Meloxicam is already in 50 of the 2000 largest hospitals in the U.S. If it can get into ~250 hospitals, that would be an indication of the potential for 100M revenue.
I would be interested in buying an offering if conducted before the end of 2020. After tax loss season, I would put it on my list of Low-Floaters if it did a reverse split in 2021.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.